This Solicitation opportunity from Department Of Defense was posted on January 8, 2025. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Top

Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program

Closed

HT9402-25-Q-9103Federal

Submission Closed01/16/2025, 06:00:00 PM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 325412

New

International

Pralidoxime Chloride/Methyl Sulfate ManufacturingThis subcontract involves the manufacture and supply of Pralidoxime chloride or methyl sulfate in solution or powder form for injection to support prime contractors on Department of National Defence projects. The required product must have a dosage strength of at least 200 mg per container and a minimum shelf-life of 36 months. The selected provider is responsible for conducting stability testing, providing quality assurance certification, and delivering complete treatment courses along with stability reports and product monographs. To be eligible, the manufacturer must hold a Health Canada Notice of Compliance under Division 8 or Division 11 authorization. This global procurement opportunity is managed by the Government of Canada and allows for performance across various international regions. Interested parties must submit their responses by November 10, 2026.

Department of National Defence

POSTED

DEADLINE

SLS Printer Consumables and Maintenance KitsThis subcontract focuses on the provision of specialized consumables and wear-and-tear replacement parts to support prime contractors working on Department of National Defence projects for the Government of Canada. The scope of supply includes engineering-grade thermoplastic powders such as PA 11, PA 12, PP, and TPU, along with critical SLS hardware components including optical cassettes, recoater blades, infrared heaters, sealing foam gaskets, and build chambers. All bulk consumables and spare parts kits are to be delivered to CFB Petawawa. The opportunity was posted on October 20, 2026, with a response deadline of November 2, 2026, falling under NAICS code 325412.

Department of National Defence

POSTED

DEADLINE

Supplier of Red Sealing Compound (NSN 8030015650423)This subcontract involves the supply of red sealing compound, identified by NSN 8030015650423, for prime contractors working under the Defense Logistics Agency. The material must be provided in 10.00 milliliter containers and strictly adhere to the DLA Master List of Technical and Quality Requirements RA001. The supplier is responsible for managing TYPE I (CODE H) shelf-life requirements and ensuring all packaging complies with MIL-STD-2073-1E and MIL-STD-129 standards. Additionally, the contractor must provide all necessary safety documentation, including SDS and HazCom labels in accordance with 29 C.F.R. 1910.1200. The performance of this contract is centered in FPO 09591-0100, with the primary objective being the delivery of packaged sealing compound and its associated safety certifications to the Department of Defense.

Defense Logistics Agency

POSTED

DEADLINE

Active Pharmaceutical Ingredient (API) SupplyThis subcontract for Active Pharmaceutical Ingredient (API) Supply involves the synthesis, purification, and bulk delivery of pharmaceutical-grade Benzocaine and Menthol. The provider supports prime contractors fulfilling requirements for the Department of Defense Medical Supply Chain Pharm FSA, ensuring all raw chemical components meet strict USP and ISO manufacturing standards through the use of HPLC purity testing. The performance of this contract is centered at Fort Campbell, Kentucky, under NAICS code 325412. The solicitation was posted on October 19, 2026, with a response deadline of October 26, 2026.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Benzocaine and Menthol Lozenge SupplyThis subcontract involves the manufacture and supply of finished Benzocaine and Menthol lozenges to prime contractors supporting the Department of Defense Medical Supply Chain Pharm FSA. The provider is responsible for producing and quality-testing pharmaceutical lozenges within FDA-compliant facilities adhering to Good Manufacturing Practice standards to ensure all delivered quantities meet strict government specifications. Administrative processes for this requirement are managed through the DLA Internet Bid Board System for quote submissions. The performance of the contract is centered at Fort Campbell, and the procurement falls under NAICS code 325412 for pharmaceutical preparation.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Supply of Moxifloxacin Hydrochloride Tablets (400 MG)This subcontract, managed by the Medical Supply Chain Pharm FSA under the Department of Defense, involves the manufacture and supply of pharmaceutical-grade Moxifloxacin Hydrochloride Tablets (400 MG). The contractor is responsible for providing the antibiotic tablets in 30-count bottles, ensuring all products are sourced or manufactured in accordance with Good Manufacturing Practices and FDA approval and registration requirements. Logistical compliance is critical, as the contract mandates adherence to RP001 DLA Packaging Requirements and the use of climate-controlled storage and transport to maintain product integrity. Performance will take place in FPO 09591, with the primary objective of supporting prime contractors on DLA supply contracts.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Supply of Activated Charcoal, SuspensionThis subcontract, issued by the Medical Supply Chain Pharm FSA under the Department of Defense, requires the provision of activated charcoal in suspension form, identified by NSN 6505012828880. The materials must be delivered to the USS Lewis B Puller ESB 3, with all shipments adhering to strict DLA packaging requirements and technical specifications. The contract falls under NAICS code 325412 and is intended for prime contractors supporting DLA supply operations. Resellers are specifically required to comply with the Non-Manufacturer Rule to ensure eligibility. The performance location is designated as FPO 09591, with a response deadline set for October 26, 2026.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Supply of 4% Chlorhexidine Gluconate Surgical DetergentThis subcontract involves the supply of FDA-regulated 4% Chlorhexidine Gluconate surgical detergent for prime contractors supporting Department of Defense supply contracts. The provider is responsible for manufacturing or sourcing the chemical compound in strict accordance with NSN 6505-01-101-3759 specifications and DLA Packaging Requirements RP001. To maintain quality and regulatory compliance, the product must be produced in FDA-approved pharmaceutical manufacturing facilities. The contract mandates a total shelf life of 24 months, with a requirement that the detergent possesses at least 21 months of remaining shelf life at the time of delivery. Managed under the Medical Supply Chain Pharm FSA, the performance of this contract is centered in FPO 96660, falling under NAICS code 325412.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Supply of Bupivacaine and Epinephrine InjectionThis subcontract involves the supply of Bupivacaine and Epinephrine Injection to prime contractors supporting DLA Troop Support medical supply contracts. The provider must deliver end items compliant with NSN 6505-01-189-3973, utilizing pharmaceutical-grade materials and medical-grade packaging. To qualify, the supplier is required to hold all necessary pharmaceutical manufacturing licenses and maintain FDA approval for the specific drug formulation. Managed by the Department of Defense under the Medical Supply Chain Pharm FSA, the contract specifies the delivery of injectable medication quantities as outlined in the award. The performance location is designated as FPO 09591, and the procurement falls under NAICS code 325412.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Isoniazid Tablet ManufacturingThis subcontract involves the manufacturing of Isoniazid 300 MG tablets for prime contractors supporting Department of Defense pharmaceutical supply contracts through the Medical Supply Chain Pharm FSA. The manufacturer is responsible for producing tablets that conform to United States Pharmacopeia standards, packaged in bottles of 100 units. To execute this contract, the provider must utilize pharmaceutical grade API, specialized tablet pressing equipment, and a USP-compliant quality control laboratory. Strict regulatory adherence is required, including the maintenance of active FDA registration and continuous USP compliance. The performance of this contract is centered in FPO 09591, with the primary objective of delivering finished pharmaceutical products that meet all specified government quality and safety benchmarks.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Tetrahydrozoline Hydrochloride Ophthalmic Solution SupplierThis subcontract involves the supply of Tetrahydrozoline Hydrochloride Ophthalmic Solution, USP (0.05%, 15 ML) to support prime contractors under DLA Troop Support medical supply contracts. The selected provider is responsible for manufacturing or sourcing the pharmaceutical solution in accordance with USP standards, utilizing sterile ophthalmic bottling and packaging. All operations must comply with FDA approval and registration requirements for pharmaceutical manufacturing. The contract is managed by the Department of Defense under the Medical Supply Chain Pharm FSA. Physical deliveries of the ophthalmic solution are to be made to either the prime contractor or the Naval Med Readiness Logistics Command, with the place of performance located in Williamsburg, Virginia.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Supply of Tolnaftate Powder, USP 1%This subcontract through the Department of Defense Medical Supply Chain Pharm FSA involves the supply of Tolnaftate Powder, USP 1%, to prime contractors on DLA Troop Support medical supply contracts. The requirement is for 15 bottles of 45 GM powder, identified by NSN 6505014807897, which must strictly adhere to USP 1% standards and the DLA Master List of Technical and Quality Requirements. Eligible providers must possess the necessary pharmaceutical manufacturing and distribution licenses to fulfill the order. The performance of this contract is designated for FPO 09591, with a response deadline set for October 26, 2026.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

1 day ago

DEADLINE

in 5 days

General Info

Agency

Department Of Defense → Defense Health Agency

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Place of Performance

San Antonio, TX, 78230, USA

Set-Aside

NONE

Documents

Amendment 0001 to Solicitation HT9402-25-Q-9103

1 page · amendment

High

DoD Price List - Endocrine Agents Miscellaneous (Feb 2025)

20 pages · rfq

High

DOD Price List - Oncological Agents (Feb 2025)

16 pages · rfq

High

DoD P&T Price List - Targeted Immunomodulatory Biologics (IL-23)

24 pages · rfq

High

DoD P&T Price List - White Blood Cell Stimulants (Filgrastims)

19 pages · rfq

High

DoD Uniform Formulary Price List - Antibiotics (Tetracyclines)

16 pages · rfq

High

DoD Uniform Formulary Price List - Cystic Fibrosis Agents (Feb 2025)

20 pages · rfq

High

DoD Uniform Formulary Price List - Miscellaneous Insulin Device

16 pages · rfq

High

DoD Uniform Formulary Price List - Neurological Agents Miscellaneous

16 pages · rfq

High

DoD Uniform Formulary Price List - Oncological Agents (Feb 2025)

16 pages · rfq

High

Imkeldi Price List - Oncological Agents (Chronic Myelogenous Leukemia)

rfq

High

Price List - Hympavzi - Antihemophilic Factors

16 pages · rfq

High

RFQ HT9402-25-Q-9103 - Uniform Formulary Pharmaceutical Agents

rfq

High

UF BPA NDC Price List - Antilipidemics-2 (Feb 2025)

20 pages · rfq

High

AI Contract Breakdown

Uniform Contract Format

Contract not broken down yet

CLEATUS splits the solicitation into Uniform Contract Format (UCF) sections: scope, pricing, deliverables, and evaluation criteria.

Timeline

1 update

PhaseClosed

PostedDec 19

Solicitation

Notice updatedJan 8

The notice description changed.

Response DeadlineJan 16

Deadline has passed

Submission Closed

01/16/2025, 06:00:00 PM UTC

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

AgencyDepartment Of Defense → Defense Health Agency

Contacts2 people available

OfficeAURORA, CO, 80011, USA

Organization / AgencyDepartment Of Defense → Defense Health Agency

Office AddressAURORA, CO, 80011, USA

Contacts

Tracy Banks

contact@example.gov

Patricia Tyson

contact@example.gov

Full Description

The Department of Defense (DoD) is required by law (10 U.S.C. - 1074g) to establish aneff ective, eff icient, integrated pharmacy benefits program for the Military Health System(MHS) which includes the purchase pharmaceutical agents. The law and implementingregulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy andTherapeutics (P&T) Committee will consider the relative clinical eff ectiveness and relativecost eff ectiveness of pharmaceutical agents in a therapeutic class in recommending theselection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, theclassification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF),Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&TCommittee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within DrugClasses identified for placement on the UF has been issued to obtain quotes from industry.The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements(UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP)based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following February 2025 newly approved drugs will be reviewed: The RFQ, including UF BPA and UF ADP appendices are attached herein. The instructions,important deadlines, and points of contact are in document, RFQ HT9402-25-Q-9103. a. Alyftrek - Cystic Fibrosis Agents - NA b. Attruby - Neurological Agents Misc - NA c. Crenessity - Endocrine Agents Miscellaneous - NA d. Danziten - Oncological Agents - NA e. Emrosi -Antibiotics - Tetracyclines f. Hympavzi - Antihemophilic Factors - NA g. Imkeldi - Oncological Agents - Chronic Myelogenous Leukemia h. Nypozi - White Blood Cell Stimulants - Filgrastims i. Omni pod 5 Libre2Plus G6 - Insulins - Miscellaneous Insulin Device j. Revuforj - Oncological Agents - NA k. Tryngolza - Antilipidemics-2 - NA l. Wezlana - Targeted Immunomodulatory Biologics - IL-23 Pre-quotation teleconference is on January 8, 2025. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submittedvia e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2.